Decabromodiphenyl ether causes insulin resistance and glucose and lipid metabolism disorders in mice

Table 2 Comparisons of fasting blood glucose, homeostatic assessment model of insulin resistance, insulin sensitivity index, and insulin of mice in each group

Group	FINS (mIU/L)	ISI	HOMA-IR	FBG
High dose	20.91 ± 0.96a,b,c	0.78 ± 0.13a,b,c	8.38 ± 0.44a	8.85 ± 0.35a,b,c
Medium-high dose	21.71 ± 0.56a,b,c	0.94 ± 0.11a,b,c	8.28 ± 0.37a	8.58 ± 0.32a,b,c
Medium dose	23.87 ± 0.46a,c	1.05 ± 0.32a,c	8.15 ± 0.43a	7.81 ± 0.49a
Medium-low dose	24.89 ± 0.27a,c	1.08 ± 0.11a,c	7.76 ± 0.53	7.02 ± 0.44
Low dose	26.02 ± 0.84a	1.41 ± 0.21	7.56 ± 0.61	6.53 ± 0.39
Control	27.37 ± 0.28	1.57 ± 0.08	7.57 ± 0.65	6.52 ± 0.68
F value	61.06	2.968	2.719	28.574
P value	0.001	0.027	0.038	0.001

^aP < 0.05 compared with the control group.

^bP < 0.05 compared with the medium dose group.

^cP < 0.05 compared with the low dose group. FINS: Fasting insulin; ISI: Insulin sensitivity index; HOMA-IR: Homeostatic assessment model of insulin resistance; FBG: Fasting blood glucose.